Clinical Trial

Optimizing Endobronchial Ultrasound Sampling for Molecular Markers for NSCLC

Study acronym: OPTIMAL

Active, Not Recruiting

Record status

This record was last updated January 26, 2026 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.

Summary

In this monocentric randomized controlled trial, 120 potential non small cell lung cancer (NSCLC) patients for which tissue diagnosis and material for next generation sequencing (NGS) is required for clinical management will be approached the day of their endobronchial ultrasound to participate in the study. They will be randomized to 2 vs 3 passes/lymph node and will all undergo liquid biopsy. The co-primary outcomes are 1)the rate of obtention of adequate material for NGS testing with 2 vs 3 passes/lymph node and 2)the percentage of patients for which liquid biopsy allows to identify clinically pertinent findings not available from tissue biopsy

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2022-09-27.

Status change: Not Yet Recruiting → Active, Not Recruiting 2026-01-23

Trial Details

NCT Number	NCT05560776
Lead Sponsor	Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Conditions	Lung Cancer, Non Small Cell Lung Cancer, Circulating Tumor Cell
Enrollment	120 participants
Start Date	2023-05-01
Primary Completion	2026-05-01 (estimated)
Study Completion	2026-05-01 (estimated)
Updated on ClinicalTrials.gov	2026-01-26